{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:13:14Z","timestamp":1790489594726,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ucl.2008.07.007","type":"journal-article","created":{"date-parts":[[2008,11,7]],"date-time":"2008-11-07T20:09:02Z","timestamp":1226088542000},"page":"687-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Systemic Therapy for Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Glenn S.","family":"Kroog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib1","first-page":"43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.007_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R","article-title":"Classification of renal cell carcinoma: workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)","volume":"80","author":"St\u00f6rkel","year":"1997","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.007_bib3","first-page":"950","article-title":"Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype","volume":"168","author":"Zisman","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2008.07.007_bib4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/PAS.0b013e318031ffff","article-title":"Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum","volume":"31","author":"Argani","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.007_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ucl.2008.07.007_bib6","doi-asserted-by":"crossref","first-page":"6282S","DOI":"10.1158\/1078-0432.CCR-050013","article-title":"Genetic basis of cancer of the kidney: disease-specific approaches to therapy","volume":"10","author":"Linehan","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.007_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/sj.bjc.6602978","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"94","author":"Patel","year":"2006","journal-title":"Br J Cancer"},{"issue":"2 Pt 2","key":"10.1016\/j.ucl.2008.07.007_bib8","doi-asserted-by":"crossref","first-page":"671s","DOI":"10.1158\/1078-0432.CCR-06-1870","article-title":"Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics","volume":"13","author":"Linehan","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ucl.2008.07.007_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib10","first-page":"42","article-title":"Chemotherapy for advanced renal-cell carcinoma: 1983\u20131993","volume":"22","author":"Yagoda","year":"1995","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.007_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0094-0143(21)00489-4","article-title":"Cytotoxic chemotherapy for advanced renal cell carcinoma","volume":"20","author":"Yagoda","year":"1993","journal-title":"Urol Clin North Am"},{"issue":"2C","key":"10.1016\/j.ucl.2008.07.007_bib12","first-page":"1541","article-title":"Chemotherapy for renal cell carcinoma","volume":"19","author":"Hartmann","year":"1999","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.ucl.2008.07.007_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJM199609193351207","article-title":"Renal-cell carcinoma","volume":"335","author":"Motzer","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.007_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0094-0143(03)00031-4","article-title":"Chemotherapeutic strategies for renal cell carcinoma","volume":"30","author":"Milowsky","year":"2003","journal-title":"Urol Clin North Am"},{"issue":"10","key":"10.1016\/j.ucl.2008.07.007_bib15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6602209","article-title":"Phase II clinical trial of capecitabine and gemcitabine chemotherapy in\u00a0patients with metastatic renal carcinoma","volume":"91","author":"Waters","year":"2004","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2008.07.007_bib16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/cncr.22117","article-title":"A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008","volume":"107","author":"Stadler","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.007_bib17","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/cncr.20541","article-title":"Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma","volume":"101","author":"Nanus","year":"2004","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.10204","article-title":"Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature","volume":"94","author":"Milowsky","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2008.07.007_bib19","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2008.07.007_bib21","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ucl.2008.07.007_bib22","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N Engl J Med"},{"issue":"9286","key":"10.1016\/j.ucl.2008.07.007_bib23","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa\u2013based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ucl.2008.07.007_bib24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.007_bib25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bbmt.2006.03.011","article-title":"Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study","volume":"12","author":"Rini","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbmt.2006.09.011","article-title":"What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma","volume":"13","author":"Ueno","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.007_bib27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdl086","article-title":"Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe","volume":"17","author":"Barkholt","year":"2006","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.ucl.2008.07.007_bib28","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.007_bib29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.mou.0000240305.78205.77","article-title":"New treatment approaches in metastatic renal cell carcinoma","volume":"16","author":"Mancuso","year":"2006","journal-title":"Curr Opin Urol"},{"issue":"5 Pt B","key":"10.1016\/j.ucl.2008.07.007_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1464-410X.2007.06833.x","article-title":"Signal-transduction inhibitors in renal cell carcinoma","volume":"99","author":"Vogelzang","year":"2007","journal-title":"BJU Int"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.007_bib31","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"Sun","year":"2003","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ucl.2008.07.007_bib34","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.007_bib35","doi-asserted-by":"crossref","first-page":"747s","DOI":"10.1158\/1078-0432.CCR-06-2063","article-title":"Sorafenib in renal cell carcinoma","volume":"13","author":"Flaherty","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.007_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","article-title":"Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors","volume":"23","author":"Strumberg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2008.07.007_bib37","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.007_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J\u00a0Med"},{"issue":"8","key":"10.1016\/j.ucl.2008.07.007_bib39","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib40","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results","volume":"25","author":"Szczylik","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib41","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1200\/jco.2007.25.18_suppl.5026","article-title":"A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)","volume":"25","author":"Amato","year":"2007","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"20","key":"10.1016\/j.ucl.2008.07.007_bib42","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.007_bib43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ucl.2008.07.007_bib44","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":"Cancer and Leukemia Group B 90206: a randomized phase III trial of\u00a0interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma","volume":"10","author":"Rini","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"9605","key":"10.1016\/j.ucl.2008.07.007_bib45","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"31","key":"10.1016\/j.ucl.2008.07.007_bib46","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ucl.2008.07.007_bib47","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"48","key":"10.1016\/j.ucl.2008.07.007_bib48","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1038\/sj.onc.1209887","article-title":"When translation meets transformation: the mTOR story","volume":"25","author":"Averous","year":"2006","journal-title":"Oncogene"},{"issue":"48","key":"10.1016\/j.ucl.2008.07.007_bib49","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"mTOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.007_bib50","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.ucl.2008.07.007_bib51","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ucl.2008.07.007_bib53","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ucl.2008.07.007_bib54","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2006.10.5916","article-title":"Phase I\/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ucl.2008.07.007_bib55","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib56","article-title":"Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-\u03b1 (IFN) or the combination of IFN+TEMSR","volume":"25","author":"Parasuraman","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib57","article-title":"Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)","volume":"25","author":"Dutcher","year":"2007","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib58","article-title":"A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)","volume":"25","author":"Jac","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib59","article-title":"Phase I study of PTK787\/ZK222584 (PTK\/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients","volume":"25","author":"Speca","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ucl.2008.07.007_bib60","unstructured":"Torisel prescribing information, Wyeth Pharmaceuticals, Inc. Philadelphia, PA."},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib61","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/jco.2007.25.18_suppl.5099","article-title":"Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"25","author":"Feldman","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib62","article-title":"Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): results of a dose-finding study","volume":"25","author":"Kondagunta","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.007_bib63","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","article-title":"Safety and anti-tumor activity of sorafenib (Nexavar((R))) in combination with other anti-cancer agents: a review of clinical trials","volume":"61","author":"Takimoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"10.1016\/j.ucl.2008.07.007_bib64","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2007.11.1047","article-title":"Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group","volume":"25","author":"Ryan","year":"2007","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ucl.2008.07.007_bib65","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1200\/JCO.2007.10.8613","article-title":"Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer","volume":"25","author":"Gollob","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18S (June 20 Supplement)","key":"10.1016\/j.ucl.2008.07.007_bib66","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/jco.2006.24.18_suppl.3004","article-title":"Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab","volume":"25","author":"Azad","year":"2006","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.007_bib67","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1359-6349(05)81741-0","article-title":"Clinical synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors: early results from a phase I study of sorafenib (BAY 43-9006) and bevacizumab","volume":"3","author":"Posadas","year":"2005","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ucl.2008.07.007_bib68","series-title":"Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). American Association for Cancer Research: molecular targets and cancer therapeutics 2007; October 2\u201326, 2007","author":"Puzanov","year":"2007"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib69","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies","volume":"25","author":"Patnaik","year":"2007","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib70","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/jco.2007.25.18_suppl.5034","article-title":"Phase I\/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results","volume":"25","author":"Merchan","year":"2007","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib71","article-title":"Sequential therapy with sorafenib and sunitinib in renal cell carcinoma","volume":"25","author":"Dham","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib72","article-title":"Sequential use of sorafenib and sunitinib in renal cancer: retrospective analysis in 90 patients","volume":"25","author":"Sablin","year":"2007","journal-title":"J Clin Oncol\u00a0(Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib73","article-title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment","volume":"25","author":"Drabkin","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib74","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/jco.2007.25.18_suppl.5035","article-title":"Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers","volume":"25","author":"George","year":"2007","journal-title":"J\u00a0Clin Oncol (Meeting Abstracts)"},{"issue":"18S","key":"10.1016\/j.ucl.2008.07.007_bib75","article-title":"Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance","volume":"25","author":"Hajdenberg","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18S (June 20 Supplement)","key":"10.1016\/j.ucl.2008.07.007_bib76","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1200\/jco.2007.25.18_suppl.5032","article-title":"Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib","volume":"25","author":"Rini","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib77","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1200\/jco.2007.25.18_suppl.5031","article-title":"Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT)","volume":"25","author":"Hutson","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.ucl.2008.07.007_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2008.07.007_bib79","first-page":"1387","article-title":"Role of transforming growth factor-alpha in von Hippel-Lindau (VHL)-\/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis","volume":"98","author":"de Paulsen","year":"2001","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10.1016\/j.ucl.2008.07.007_bib80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1023\/A:1025472712456","article-title":"Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma","volume":"21","author":"Drucker","year":"2003","journal-title":"Invest New Drugs"},{"issue":"23","key":"10.1016\/j.ucl.2008.07.007_bib81","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1158\/1078-0432.CCR-04-0310","article-title":"A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma","volume":"10","author":"Dawson","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib82","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1200\/jco.2007.25.18_suppl.5097","article-title":"Phase I\/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"25","author":"Patel","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"11","key":"10.1016\/j.ucl.2008.07.007_bib83","first-page":"2729","article-title":"Phase I\/II radioimmunotherapy trial with iodine-131\u2013labeled monoclonal antibody G250 in metastatic renal cell carcinoma","volume":"4","author":"Divgi","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2008.07.007_bib84","first-page":"13","article-title":"A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma","volume":"7","author":"Davis","year":"2007","journal-title":"Cancer Immun"},{"issue":"2","key":"10.1016\/j.ucl.2008.07.007_bib85","doi-asserted-by":"crossref","first-page":"74","DOI":"10.14712\/fb2003049020074","article-title":"A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients","volume":"49","author":"Varga","year":"2003","journal-title":"Folia Biol"},{"key":"10.1016\/j.ucl.2008.07.007_bib86","first-page":"14","article-title":"A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma","volume":"7","author":"Davis","year":"2007","journal-title":"Cancer Immun"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib87","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-5347(05)00040-6","article-title":"A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma","volume":"175","author":"Bleumer","year":"2006","journal-title":"J Urol"},{"issue":"18 Suppl","key":"10.1016\/j.ucl.2008.07.007_bib88","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/jco.2007.25.18_suppl.5094","article-title":"Final results from phase II study of volociximab, an {alpha}5{beta}1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma (mCCRCC)","volume":"25","author":"Yazji","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","article-title":"Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma","volume":"26","author":"Choueiri","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2008.07.007_bib90","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ucl.2008.07.007_bib91","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.ucl.2008.07.007_bib92","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.ucl.2008.07.007_bib93","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor\u2013induced responses and tumor growth after oral administration","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer research"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014308000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014308000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:21:27Z","timestamp":1758806487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014308000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0094014308000670"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2008.07.007","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy for Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2008.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}